	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S0-PMC2582131	PMC2582131	11/2008	S0-PMC2582131	['Maternal Plasma 25-Hydroxyvitamin D concentrations and the risk for Gestational diabetes mellitus\n\nabstract\n\nbackground\nEVIDENCE is ACCUMULATING for a ROLE of Vitamin D in maintaining normal Glucose Homeostasis.']	[('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 151)]	3	"[('UBERON_0000976', 'humerus', 0, 'Maternal'), ('UBERON_0001969', 'blood plasma', 9, 'Plasma'), ('CHEBI_27844', ""2',3'-cyclic AMP"", 16, '25-Hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 68, 'Gestational'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_17234', 'glucose', 191, 'glucose'), ('GO_0042593', 'glucose homeostasis', 191, 'glucose homeostasis')]"
S14-PMC2582131	PMC2582131	11/2008	S14-PMC2582131	['HOWEVER, the ubiquitous distribution of Intracellular Vitamin D Receptor across diverse Tissues[1]and the EMERGING epidemiological EVIDENCE DOCUMENTING INCREASED RISKS of hypertension[2],[3], Cardiovascular disease[4]–[7], and selected cancers[1],[8]ASSOCIATED with Vitamin D deficiency underscore the pleiotropic actions of Vitamin D. evidence is also accumulating for a ROLE of Vitamin D in maintaining normal Glucose Homeostasis.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 106), ('INCOMPLETE_EVIDENCE', 140), ('IMPORTANT_CONSIDERATION', 152), ('SUPERFICIAL_RELATIONSHIP', 250), ('SUPERFICIAL_RELATIONSHIP', 372)]	6	[('GO_0005622', 'intracellular anatomical structure', 40, 'intracellular'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 54, 'vitamin D receptor'), ('UBERON_0000479', 'tissue', 88, 'tissues'), ('UBERON_0004535', 'cardiovascular system', 192, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 325, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('CHEBI_17234', 'glucose', 412, 'glucose'), ('GO_0042593', 'glucose homeostasis', 412, 'glucose homeostasis')]
S21-PMC2582131	PMC2582131	11/2008	S21-PMC2582131	['data on the ROLE of Vitamin D in Glucose Homeostasis during Pregnancy and the development of Gestational Diabetes Mellitus (gdm) are SCANT and findings are INCONSISTENT.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 133), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('GO_0042593', 'glucose homeostasis', 33, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0035193', 'larval central nervous system remodeling', 93, 'gestational diabetes mellitus')]
S86-PMC2582131	PMC2582131	11/2008	S86-PMC2582131	['it has become increasingly CLEAR that Vitamin D has physiological functions beyond bone health[6]; Vitamin D receptors were Expressed in a large number of other Tissues including those INVOLVED in the Regulation Of Glucose Metabolism, such as Muscle and Pancreatic Β Cells[1].']	[('PROBABLE_UNDERSTANDING', 27), ('SUPERFICIAL_RELATIONSHIP', 185)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0010467', 'gene expression', 124, 'expressed'), ('UBERON_0000479', 'tissue', 161, 'tissues'), ('GO_0010906', 'regulation of glucose metabolic process', 201, 'regulation of glucose metabolism'), ('CHEBI_17234', 'glucose', 215, 'glucose'), ('CL_0000187', 'muscle cell', 243, 'muscle ...'), ('CL_0000173', 'pancreatic D cell', 254, 'pancreatic β cells'), ('UBERON_0001264', 'pancreas', 254, 'pancreatic')]
S90-PMC2582131	PMC2582131	11/2008	S90-PMC2582131	['second, Vitamin D CAN promote Insulin sensitivity by stimulating the Expression of Insulin receptors and enhancing Insulin responsiveness for Glucose transport.']	[('INCOMPLETE_EVIDENCE', 18)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('GO_0010467', 'gene expression', 69, 'expression'), ('PR_000045358', 'insulin family protein', 83, 'insulin'), ('PR_000045358', 'insulin family protein', 115, 'insulin'), ('CHEBI_17234', 'glucose', 142, 'glucose')]
S92-PMC2582131	PMC2582131	11/2008	S92-PMC2582131	['lastly, IT IS POSSIBLE that the OBSERVED inverse ASSOCIATION of Plasma 25-[Oh] D with gdm risk REFLECTS the IMPACT of other components of major endogenous and exogenous sources of Vitamin D on Glucose Homeostasis through OTHER pathways.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 32), ('SUPERFICIAL_RELATIONSHIP', 49), ('SUPERFICIAL_RELATIONSHIP', 95), ('SUPERFICIAL_RELATIONSHIP', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 221)]	6	[('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 71, '25-[OH] D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_17234', 'glucose', 193, 'glucose'), ('GO_0042593', 'glucose homeostasis', 193, 'glucose homeostasis')]
S121-PMC2582131	PMC2582131	11/2008	S121-PMC2582131	['such EVIDENCE is valuable in view of the LIMITED prospective DATA on the RELATION of circulating Vitamin D status to impaired Glucose tolerance in either Pregnant or non-Pregnant Individuals.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 73)]	3	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('GO_0007565', 'female pregnancy', 170, 'pregnant'), ('NCBITaxon_1', 'root', 179, 'individuals')]
S125-PMC2582131	PMC2582131	11/2008	S125-PMC2582131	['intervention studies[14],[40]–[44]assessing the EFFECT of Vitamin D and Calcium supplements on Glucose Metabolism among non-Pregnant Individuals have yielded MIXED results, which is AT LEAST PARTLY DUE TO VARIATIONS in the dose of supplementation and the duration of follow up.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('PROBABLE_UNDERSTANDING', 182), ('INCOMPLETE_EVIDENCE', 191), ('PROBLEM_COMPLICATION', 198), ('DIFFICULT_TASK', 205)]	6	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 72, 'calcium'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnant'), ('NCBITaxon_1', 'root', 133, 'individuals')]
S115-PMC3356951	PMC3356951	4/2012	S115-PMC3356951	['[89]\n\ntype 2 diabetes\na trial of nondiabetic patients aged 65 years and older FOUND that those who received 700 iu of Vitamin D (plus calcium) had a smaller rise in fasting Plasma Glucose over 3 years versus those who received placebo.']	[('INCOMPLETE_EVIDENCE', 78)]	1	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 173, 'plasma'), ('CHEBI_17234', 'glucose', 180, 'glucose')]
S18-PMC3470091	PMC3470091	9/2012	S18-PMC3470091	['these CAN cause Vitamin D deficiency in mothers’ Milk as the only source of Vitamin D for babies.6\nthere are EVIDENCES SHOWING the ROLE of Vitamin D in keeping normal Glucose Homeostasis.7-10resistance to Insulin and destruction of Insulin secretion in Human and Animal MODELS has CONSIDERABLY been RELATED to Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 119), ('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 270), ('ANOMALY_CURIOUS_FINDING', 281), ('SUPERFICIAL_RELATIONSHIP', 299)]	7	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001913', 'milk', 49, 'milk'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_17234', 'glucose', 167, 'glucose'), ('GO_0042593', 'glucose homeostasis', 167, 'glucose homeostasis'), ('PR_000045358', 'insulin family protein', 205, 'insulin'), ('PR_000045358', 'insulin family protein', 232, 'insulin'), ('NCBITaxon_9606', 'Homo sapiens', 253, 'human'), ('NCBITaxon_33208', 'Metazoa', 263, 'animal'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D')]
S144-PMC3659910	PMC3659910	1/2013	S144-PMC3659910	['lower maternal Vitamin D status was ASSOCIATED with lower bone Mineral concentration and impaired Glucose Homeostasis in newborn infants.']	[('SUPERFICIAL_RELATIONSHIP', 36)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_46662', 'mineral', 63, 'mineral'), ('CHEBI_17234', 'glucose', 98, 'glucose'), ('GO_0042593', 'glucose homeostasis', 98, 'glucose homeostasis')]
S53-PMC3695234	PMC3695234	7/2013	S53-PMC3695234	['this Molecule is subsequently Metabolized in the Kidney to its active form, 1,25(Oh)2D3, which plays a key ROLE in Skeletal and Extraskeletal functions, including immunity and Glucose Metabolism.8since it is absorbed via the skin, the IMPACT of Vitamin D levels on allergic skin diseases is of particular interest.']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 235)]	2	[('CHEBI_36357', 'polyatomic entity', 5, 'molecule'), ('GO_0008152', 'metabolic process', 30, 'metabolized'), ('UBERON_0002113', 'kidney', 49, 'kidney'), ('CHEBI_37983', 'sulfur-35 atom', 76, '1'), ('CHEBI_17996', 'chloride', 77, ','), ('CHEBI_73394', 'Ala-Ser', 78, '25(OH)2D3'), ('UBERON_0004288', 'skeleton', 115, 'skeletal'), ('UBERON_0001431', 'distal carpal bone 2', 128, 'extraskeletal'), ('CHEBI_17234', 'glucose', 176, 'glucose'), ('GO_0006006', 'glucose metabolic process', 176, 'glucose metabolism'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]
S44-PMC3702245	PMC3702245	6/2013	S44-PMC3702245	['with INCREASING INTEREST in the ROLE of Vitamin D in Glucose Homeostasis, the ASSOCIATION between maternal Serum 25(Oh)D concentration in early Pregnancy and the risk of Gestational diabetes mellitus was investigated in a study from the national institutes of health, bethesda, md.85the authors FOUND that maternal Vitamin D deficiency [serum 25(Oh)D < 50 nmol/l] was ASSOCIATED with a higher risk of Gestational diabetes mellitus (adjusted odds ratio 2.66; ci 1.01–7.02).']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 78), ('INCOMPLETE_EVIDENCE', 295), ('SUPERFICIAL_RELATIONSHIP', 368)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042593', 'glucose homeostasis', 53, 'glucose homeostasis'), ('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_71657', 'versiconol acetate', 113, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 113, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 343, '25(OH)D'), ('GO_0007565', 'female pregnancy', 401, 'gestational')]
S87-PMC3717170	PMC3717170	5/2013	S87-PMC3717170	['2; unpublished data) and improved MARKERS of adiposity and Vitamin D status (Plasma concentrations of Glucose, Insulin, adiponectin, 25(Oh)D3, 1,25(Oh)2D3, and pth), BUT an increased Plasma Ca2+.']	[('SUPERFICIAL_RELATIONSHIP', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 77, 'plasma'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('PR_000045358', 'insulin family protein', 111, 'insulin'), ('CHEBI_62946', 'ammonium sulfate', 133, '25(OH)D3'), ('CHEBI_73394', 'Ala-Ser', 145, '25(OH)2D3'), ('UBERON_0001969', 'blood plasma', 183, 'plasma'), ('CHEBI_29108', 'calcium(2+)', 190, 'Ca2+.')]
S43-PMC3760821	PMC3760821	9/2013	S43-PMC3760821	['further, it HAS BEEN SUGGESTED that Vitamin D CAN alter Glucose and Insulin Metabolism, and, THEREFORE, IMPACT on energy available to the foetus[11].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 46), ('PROBABLE_UNDERSTANDING', 93), ('SUPERFICIAL_RELATIONSHIP', 104)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('GO_0007369', 'gastrulation', 56, 'glucose ...'), ('GO_1901142', 'insulin metabolic process', 68, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 68, 'insulin')]
S174-PMC3760821	PMC3760821	9/2013	S174-PMC3760821	['POTENTIAL mechanisms by which Vitamin D MIGHT INFLUENCE Glycaemic Control in t1dm include, the IMPACT of this Vitamin on Intracellular Calcium Regulation and, THUS, Glucose transport in target Tissues, INFLUENCES on Insulin receptor Expression and the EFFECT of Vitamin D on systemic inflammation ASSOCIATED with Insulin resistance[31],[32].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 95), ('PROBABLE_UNDERSTANDING', 159), ('SUPERFICIAL_RELATIONSHIP', 202), ('SUPERFICIAL_RELATIONSHIP', 252), ('SUPERFICIAL_RELATIONSHIP', 297)]	8	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0051162', 'L-arabitol metabolic process', 56, 'glycaemic control'), ('CHEBI_33229', 'vitamin (role)', 110, 'vitamin'), ('GO_0005622', 'intracellular anatomical structure', 121, 'intracellular'), ('GO_0006260', 'DNA replication', 121, 'intracellular'), ('GO_0051303', 'establishment of chromosome localization', 135, 'calcium regulation'), ('CHEBI_17234', 'glucose', 165, 'glucose'), ('UBERON_0000479', 'tissue', 193, 'tissues'), ('PR_000045358', 'insulin family protein', 216, 'insulin'), ('GO_0010467', 'gene expression', 233, 'expression'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('PR_000045358', 'insulin family protein', 313, 'insulin')]
S177-PMC3760821	PMC3760821	9/2013	S177-PMC3760821	['with respect to a causal LINK between Vitamin D repletion and improved Glucose Homeostasis, LIMITED STUDIES HAVE REPORTED substantial improvements in Glycaemic Control (hba1clevels) in t1dm patients who achieved higher circulating 25Ohd levels via supplementation[36],[37].']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 92), ('INCOMPLETE_EVIDENCE', 108)]	3	"[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('GO_0042593', 'glucose homeostasis', 71, 'glucose homeostasis'), ('GO_0051162', 'L-arabitol metabolic process', 150, 'glycaemic control'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 231, '25OHD')]"
S178-PMC3760821	PMC3760821	9/2013	S178-PMC3760821	['the results of a recent systematic review SUGGEST a weak EFFECT of Vitamin D supplementation in reducing fasting Glucose and improving Insulin resistance in patients with t2dm or impaired glucose tolerance[38].']	[('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('PR_000045358', 'insulin family protein', 135, 'insulin')]
S0-PMC3809191	PMC3809191	1/2013	S0-PMC3809191	['frequency of Vitamin D deficiency in Pregnant diabetics at baskent university hospital, istanbul\n\nabstract\nobjective: TO FIND out the frequency of Vitamin D deficiency and its RELATION with Glucose parameters and the incidence of Gestational diabetes (gdm).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 118), ('SUPERFICIAL_RELATIONSHIP', 176)]	2	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_17234', 'glucose', 190, 'glucose'), ('GO_0007565', 'female pregnancy', 230, 'gestational')]
S153-PMC3855580	PMC3855580	10/2013	S153-PMC3855580	['we have PREVIOUSLY SHOWN that the ASSOCIATION between maternal Vitamin D deficiency [38] and Glucose intolerance [11,14] with offspring homa-ir was present at 9.5\xa0years of age, but NOT at 5\xa0years of age.']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 34), ('ANOMALY_CURIOUS_FINDING', 181)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_17234', 'glucose', 93, 'glucose')]
S1072-PMC4113768	PMC4113768	7/2014	S1072-PMC4113768	['methods: we determined concentrations of Serum 25 Hydroxy-Vitamin D in RELATION to several other Metabolic BIOMARKERS including total Cholesterol, low-density lipoprotein Cholesterol (ldl-c), high density lipoprotein-Cholesterol (Hdl-C), Triglycerides, atherogenic index, Glucose, C-Reactive Protein (crp), measures of adiposity, and Blood pressure values in a cross-sectional analysis in 180 saudi Postmenopausal women aged 48 to 88 years.']	[('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 107)]	2	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_67778', '(E)-Adrienyne, [rel(threo)]-', 47, '25 hydroxy-'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0008152', 'metabolic process', 97, 'metabolic'), ('CHEBI_16113', 'cholesterol', 134, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 171, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 217, 'cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 230, 'HDL-C'), ('CHEBI_17855', 'triglyceride', 238, 'triglycerides'), ('CHEBI_17234', 'glucose', 272, 'glucose'), ('PR_000005890', 'crooked neck-like protein 1', 281, 'C-reactive protein'), ('UBERON_0000178', 'blood', 334, 'blood'), ('GO_0007595', 'lactation', 399, 'postmenopausal')]
S3066-PMC4113768	PMC4113768	7/2014	S3066-PMC4113768	['RISK FACTORS for Cardiovascular disease HAVE also BEEN ASSOCIATED with low Serum (25(Oh)D. we AIMED TO INVESTIGATE WHETHER high-dose Vitamin D supplementation CAN improve Glucose Metabolism in a population with impaired fasting Glucose and/or impaired Glucose tolerance.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 55), ('QUESTION_ANSWERED_BY_THIS_WORK', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('INCOMPLETE_EVIDENCE', 159)]	7	[('UBERON_0004535', 'cardiovascular system', 17, 'cardiovascular'), ('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_17234', 'glucose', 171, 'glucose'), ('GO_0006006', 'glucose metabolic process', 171, 'glucose metabolism'), ('CHEBI_17234', 'glucose', 228, 'glucose'), ('CHEBI_17234', 'glucose', 252, 'glucose')]
S3300-PMC4113768	PMC4113768	7/2014	S3300-PMC4113768	['there are many mechanisms whereby Vitamin D CAN reduce the RISK of cvd including reduced risk of diabetes mellitus and Metabolic syndrome, EFFECTS on Blood pressure, Cholesterol, cytokines, Endothelial disruption, Glucose Regulation, Insulin resistance, muscle strength, Respiratory infections, and vascular calcification.']	[('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 59), ('SUPERFICIAL_RELATIONSHIP', 139)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0008152', 'metabolic process', 119, 'metabolic'), ('UBERON_0000178', 'blood', 150, 'blood'), ('CHEBI_16113', 'cholesterol', 166, 'cholesterol'), ('UBERON_0001986', 'endothelium', 190, 'endothelial'), ('CHEBI_17234', 'glucose', 214, 'glucose'), ('GO_0006094', 'gluconeogenesis', 214, 'glucose regulation'), ('PR_000045358', 'insulin family protein', 234, 'insulin'), ('UBERON_0001004', 'respiratory system', 271, 'respiratory')]
S84-PMC4383226	PMC4383226	2/2015	S84-PMC4383226	['ASSOCIATIONS between Vitamin A and parasitemia were stronger among communities with a higher mean predicted Sickle Cell hemoglobin (hbs) Allele frequency or median predicted Glucose-6-Phosphate dehydrogenase deficiency (g6pdd) Allele frequency.']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CL_0000129', 'microglial cell', 108, 'sickle cell'), ('SO_0001023', 'allele', 137, 'allele'), ('CHEBI_17234', 'glucose', 174, 'glucose'), ('CHEBI_18367', 'phosphate(3-)', 184, 'phosphate'), ('SO_0001023', 'allele', 227, 'allele')]
S1-PMC4427001	PMC4427001	4/2015	S1-PMC4427001	['the AIMS of the PRESENT STUDY were TO DETERMINE Midgestational and early Postpartum Vitamin D status in Pregnant women with and without gdm and to describe the RELATIONSHIP between Midgestational and Postpartum Vitamin D status and parallel changes of Glucose tolerance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('SUPERFICIAL_RELATIONSHIP', 160)]	4	[('GO_0007507', 'heart development', 48, 'midgestational'), ('GO_0007565', 'female pregnancy', 73, 'postpartum'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnant'), ('GO_0007507', 'heart development', 181, 'midgestational'), ('GO_0007565', 'female pregnancy', 200, 'postpartum'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_17234', 'glucose', 252, 'glucose')]
S38-PMC4427001	PMC4427001	4/2015	S38-PMC4427001	['currently, LITTLE IS KNOWN about Postpartum Vitamin D status in women with history of gdm and POSSIBLE RELATIONSHIP between 25(Oh)D Plasma levels measured at the time of gdm diagnosis and the degree of Glucose (in)tolerance Postpartum.']	[('FULL_UNKNOWN', 11), ('INCOMPLETE_EVIDENCE', 94), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0007565', 'female pregnancy', 33, 'postpartum'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 132, 'plasma'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('GO_0007565', 'female pregnancy', 224, 'postpartum')]
S40-PMC4427001	PMC4427001	4/2015	S40-PMC4427001	['THEREFORE, the AIMS of the PRESENT STUDY were (1) TO DETERMINE Midgestational and early Postpartum Vitamin D status by measuring 25(Oh)D Plasma levels in Pregnant women with and without gdm to CONFIRM the hypothetical deficiency in gdm in central european population and (2) to describe the RELATIONSHIP between Midgestational and Postpartum Vitamin D status and parallel changes of parameters characterising Glucose tolerance.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('QUESTION_ANSWERED_BY_THIS_WORK', 50), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 291)]	6	[('GO_0007507', 'heart development', 63, 'midgestational'), ('GO_0007565', 'female pregnancy', 88, 'postpartum'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 132, 'OH ... D'), ('UBERON_0001969', 'blood plasma', 137, 'plasma'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('GO_0007507', 'heart development', 312, 'midgestational'), ('GO_0007565', 'female pregnancy', 331, 'postpartum'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('CHEBI_17234', 'glucose', 409, 'glucose')]
S118-PMC4427001	PMC4427001	4/2015	S118-PMC4427001	['[26] FOUND an inverse ASSOCIATION between second trimester 25(Oh)D levels < 25\u2009nmol/l and 1\u2009hr after load Glucose (50\u2009g) levels; HOWEVER, ONLY 5% of studied women developed gdm and as mentioned above THRESHOLD for Vitamin D deficiency DIFFERED from our study.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 129), ('INCOMPLETE_EVIDENCE', 138), ('PROBABLE_UNDERSTANDING', 200), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235)]	6	[('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 59, '25(OH ... D'), ('CHEBI_17234', 'glucose', 106, 'glucose'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]
S120-PMC4427001	PMC4427001	4/2015	S120-PMC4427001	['[28] reported that prevalence of Vitamin D deficiency is higher among women with impaired Glucose tolerance or gdm in 204 iranian women but they DID NOT FIND CORRELATION with bmi or fpg.']	[('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 158)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_17234', 'glucose', 90, 'glucose')]
S143-PMC4427001	PMC4427001	4/2015	S143-PMC4427001	['rudnicki and mølsted-pedersen [45] reported that supplementation with an active form of Vitamin D (1,25(Oh)2D) was ASSOCIATED with significant decrease of plasma Glucose level and POSSIBLE EFFECT on Insulin sensitivity.']	[('SUPERFICIAL_RELATIONSHIP', 115), ('INCOMPLETE_EVIDENCE', 180), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	"[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_37958', 'dye', 99, '1,'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 101, '25(OH)2D'), ('CHEBI_17234', 'glucose', 162, 'glucose'), ('PR_000045358', 'insulin family protein', 199, 'insulin')]"
S153-PMC4427001	PMC4427001	4/2015	S153-PMC4427001	['POTENTIALLY beneficial EFFECT of Vitamin D supplementation and the PLAUSIBLE pathogenic ROLE of 25(Oh)D deficiency in the subsequent development of diabetes mellitus type 2 in women with gdm history HAS to be FURTHER explored considering the ROLE of Vitamin D in Modulating Insulin sensitivity and Glucose Metabolism.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 67), ('SUPERFICIAL_RELATIONSHIP', 88), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 209), ('SUPERFICIAL_RELATIONSHIP', 242)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('GO_0065007', 'biological regulation', 263, 'modulating'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('CHEBI_17234', 'glucose', 298, 'glucose'), ('GO_0006006', 'glucose metabolic process', 298, 'glucose metabolism')]
S137-PMC4490503	PMC4490503	6/2015	S137-PMC4490503	['gdm develops when beta cell dysfunction coexists, and MAY BE characterised by further abnormalities in adipokine and cytokine profiles, increased Free Fatty Acids (ffa), Triglycerides (tg), low Vitamin D and Endothelial dysfunction.ijms-16-13442-t001_table 1\n\ncaption (table-wrap): table 1\n\nlongitudinal studies of inflammatory markers in prediction of gdm.inflammatory markerfirst author (year)study designgdm statusgdm diagnostic criteriagestational age at testing (weeks)EFFECT in gdmmatching or adjustment for confounderstnf-αkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weekstnf-Α ↑ 34–36 weeks in gdm inversely CORRELATED with Insulin sensitivityfat massgao (2008) [65]nested case-control22 gdm 10 igt 20 ngtunknown12–20 weeks 24–32 weekstnf-Α ↑ in gdm positively CORRELATED with bmi 14–20 weeksn/ageorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmisaucedo (2011) [67]prospective60 gdm 60 ngt24–28 weeks ada criteria 2010 [68]30 weeks 6 weeks 6 months Postpartumtnf-Α ↑ in both groups at 6 weeks Tnf-Α ↑ 6months Postpartum in gdmage weightlopez-tinoco (2012) [69]case-control63 gdm 63 ngt24–28 weeks nddg criteria [70]mean ~29 weekstnf-Α ↑ in gdmbmiguillemette (2014) [71]prospective61 gdm 695 ngt24–28 weeks iadpsg criteria [44]5–16 weeks 24–28 weekstnf-Α ↑ in both groups and ASSOCIATED with Insulin resistanceage bmi tg adiponectin.il-6morrisett (2011) [72]case-control20 gdm 27 ngt26.1 ± 3.7 weeks cda criteria [73]26.1 ± 3.7 weeks 8 weeks post-partumil-6 ↑ in gdm and post-Partum, CORRELATED with Insulin sensitivity and bmibmihassiakos (2015) [74]case-control40 gdm 94 ngt24–28 weeks iadpsg criteria [44]11–14 weekil-6 ↑ in gdm and inversely RELATED to Birth weightmaternal weightleptinkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weeksleptin ↑ across Pregnancy inverse CORRELATION with Insulin sensitivity, BUT non-significant when adjusted for fat massfat massgeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmiqiu (2004) [75]prospective47 gdm 776 ngt26–28 weeks carpenter and coustan criteria [64]13 weeks10-ng/ml ↑ in leptin ASSOCIATED with 20% ↑ gdmparity bmi family history of non-Insulin dependent diabetesadiponectingeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksage ethnicity gravidity parity bmimcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weekadiponectin ↓ gdm and offspringage maternal weightwilliams (2004) [77]nested case-control41 gdm 70 ngt26–28 weeks carpenter and coustan criteria [64]13 week4.6-fold ↑ risk of gdm if adiponectin < 6.4 mcg/ml, overweight women 11-fold ↑ risk of gdmbmilain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksadiponectin < 25th 11-fold ↑ risk gdmbmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or random Glucose ≥ 8.9 mmol/l24–32 weeks↓ adiponectin ASSOCIATED with ↑ Glucose and bmibmi c-peptide Gestation genderlacroix (2013) [79]prospective38 gdm 407 ngt24–28 weeks iadpsg criteria [44]6–13 week↓ adiponectin ASSOCIATED with ↑ risk gdm (or1.12 per 1 µg/ml ↓ of adiponectin) and ASSOCIATED with Insulin sensitivitybmi hba1cianniello (2013) [39]prospective16 gdm 32 ngt24–28 weeks carpenter and coustan criteria [64]all trimesters↓ adiponectin PREDICTIVE of gdm in overweight/obesen/aweerakiet (2006) [80]prospective60 gdm 299 ngt24–28 weeks carpenter and coustan criteria [64]21–27 weekadiponectin 10 µg/ml has sensitivity of 91% and specificity of 31% for gdmbmirbp-4krzyzanovska (2008) [81]nested case-control20 gdm 22 ngt24–28 weeks carpenter and coustan criteria [64]30 weekrbp-4 ↓ in gdmn/ananda (2013) [82]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/aabetew (2013) [84]nested case-control173 gdm 187 ngt24–28 weeks carpenter and coustan criteria [64]16 weeksrbp-4 ↑ in gdm BUT NOT significant after adjustmentmaternal age ethnicityresistinlain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksno differencebmigeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or Random Glucose ≥ 8.9 mmol/l24–32 weeksnot ASSOCIATED with Glucose or Birth weightbmi c-peptide Gestation gendernanda (2012) [85]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/amcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weeksresistin ↓ in gdm and offspringage maternal weightvisfatinkrzyzanovska (2006) [86]nested case-control64 gdm 30 ngt24–28 weeks carpenter and coustan criteria [64]28–30 weeks 38–40 weeks 2 weeks post-Partumvisfatin ↑ in gdmbmiferreira (2011) [87]case-control100 gdm 300 ngt24–28 weeks who criteria 2006 [83]11–13 weekvisfatin ↑ in gdmn/a\nngt = normal Glucose tolerance; igt = impaired Glucose tolerance; fpg = fasting plasma Glucose; homa-ir = homeostasis model assessment for Insulin resistance; matsuda index = measure of Insulin sensitivity; bmi = body mass index; tg = Triglycerides; n/a = not available; ↓ = decreased levels; ↑ = increased levels; adips = australasian diabetes in Pregnancy society; ada = american diabetes association; nddg = national diabetes data group; iadpsg = international association of diabetes and Pregnancy study group; cda = canadian diabetes association; who = world health organisation.']	[('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 474), ('SUPERFICIAL_RELATIONSHIP', 689), ('SUPERFICIAL_RELATIONSHIP', 842), ('SUPERFICIAL_RELATIONSHIP', 1457), ('SUPERFICIAL_RELATIONSHIP', 1665), ('SUPERFICIAL_RELATIONSHIP', 1827), ('SUPERFICIAL_RELATIONSHIP', 2027), ('ANOMALY_CURIOUS_FINDING', 2065), ('SUPERFICIAL_RELATIONSHIP', 2387), ('SUPERFICIAL_RELATIONSHIP', 3275), ('SUPERFICIAL_RELATIONSHIP', 3437), ('SUPERFICIAL_RELATIONSHIP', 3506), ('SUPERFICIAL_RELATIONSHIP', 3670), ('ANOMALY_CURIOUS_FINDING', 4255), ('SUPERFICIAL_RELATIONSHIP', 4764)]	16	[('CHEBI_37958', 'dye', 146, 'free'), ('CHEBI_35366', 'fatty acid', 151, 'fatty acids'), ('CHEBI_17855', 'triglyceride', 170, 'triglycerides'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('UBERON_0001986', 'endothelium', 208, 'endothelial'), ('PR_000000034', 'BMP', 655, '-α'), ('PR_000045358', 'insulin family protein', 705, 'insulin'), ('PR_000000034', 'BMP', 819, '-α'), ('GO_0030254', 'protein secretion by the type III secretion system', 1131, 'postpartumTNF'), ('PR_000000034', 'BMP', 1144, '-α'), ('PR_000000134', 'tumor necrosis factor alpha', 1175, 'TNF-α'), ('GO_0007565', 'female pregnancy', 1191, 'postpartum'), ('PR_000000034', 'BMP', 1314, '-α'), ('PR_000000034', 'BMP', 1433, '-α'), ('PR_000045358', 'insulin family protein', 1473, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1636, '-6'), ('GO_0007567', 'parturition', 1657, 'partum'), ('PR_000045358', 'insulin family protein', 1681, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1801, '-6'), ('GO_0007567', 'parturition', 1838, 'birth'), ('GO_0007565', 'female pregnancy', 2009, 'pregnancy'), ('PR_000045358', 'insulin family protein', 2044, 'insulin'), ('PR_000045358', 'insulin family protein', 2445, 'insulin'), ('GO_0007565', 'female pregnancy', 3132, 'pregnant'), ('CHEBI_17234', 'glucose', 3230, 'glucose'), ('CHEBI_17234', 'glucose', 3293, 'glucose'), ('GO_0007565', 'female pregnancy', 3322, 'gestation'), ('PR_000045358', 'insulin family protein', 3522, 'insulin'), ('GO_0007565', 'female pregnancy', 4631, 'pregnant'), ('CHEBI_45267', 'praziquantel', 4722, 'random'), ('CHEBI_17234', 'glucose', 4729, 'glucose'), ('CHEBI_17234', 'glucose', 4780, 'glucose'), ('GO_0007567', 'parturition', 4791, 'birth'), ('GO_0007565', 'female pregnancy', 4817, 'gestation'), ('GO_0030164', 'protein denaturation', 5223, 'partumVisfatin'), ('CHEBI_17234', 'glucose', 5374, 'glucose'), ('CHEBI_17234', 'glucose', 5408, 'glucose'), ('CHEBI_17234', 'glucose', 5448, 'glucose'), ('PR_000045358', 'insulin family protein', 5500, 'insulin'), ('PR_000045358', 'insulin family protein', 5547, 'insulin'), ('CHEBI_17855', 'triglyceride', 5596, 'triglycerides'), ('GO_0007565', 'female pregnancy', 5709, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 5853, 'Pregnancy')]
S22-PMC4632418	PMC4632418	10/2015	S22-PMC4632418	['the ROLE of Vitamin D on Gdm Development HAS been studied, and Vitamin D deficiency APPEARS TO BE ASSOCIATED with altered Glucose Homeostasis during Pregnancy [12,13].']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 41), ('ANOMALY_CURIOUS_FINDING', 84), ('SUPERFICIAL_RELATIONSHIP', 98)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0072147', 'glomerular parietal epithelial cell fate commitment', 25, 'GDM development'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_17234', 'glucose', 122, 'glucose'), ('GO_0042593', 'glucose homeostasis', 122, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy')]
S24-PMC4632418	PMC4632418	10/2015	S24-PMC4632418	['CONTRADICTORILY, SOME STUDIES SUGGESTED that no significant differences in Vitamin D status were FOUND between women with gdm and normal Glucose tolerance [15,16].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 97)]	5	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_17234', 'glucose', 137, 'glucose')]
S34-PMC4632418	PMC4632418	10/2015	S34-PMC4632418	['study selection\noriginal research evaluating the ASSOCIATIONS between Vitamin D status and Pregnancy outcomes were scrutinized and subsequently selected if they fulfilled the following inclusion criteria: a. study population was Pregnant women without pre-existing chronic disease; b. gdm as outcome and the control were women with normal Glucose tolerance (ngt); c. contained RELEVANT data to calculate the effect size and corresponding 95% confidence intervals (ci); d. met the predefined methodological quality assessment criteria for observational studies (supplementary data box 1) [18]; e. only studies published in english were considered.']	[('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 377)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 229, 'pregnant'), ('CHEBI_17234', 'glucose', 339, 'glucose')]
S115-PMC4632418	PMC4632418	10/2015	S115-PMC4632418	['in words, there is a CONNECTION between Glucose Metabolism and Vitamin D pathways, EVEN IF FURTHER STUDIES based on larger population ARE NEEDED to get more evidence about the topic.']	[('SUPERFICIAL_RELATIONSHIP', 21), ('ANOMALY_CURIOUS_FINDING', 83), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 88), ('FUTURE_WORK', 91), ('FUTURE_WORK', 99), ('FUTURE_WORK', 134)]	6	[('CHEBI_17234', 'glucose', 40, 'glucose'), ('GO_0006006', 'glucose metabolic process', 40, 'glucose metabolism'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
S109-PMC4934634	PMC4934634	11/2015	S109-PMC4934634	['Gestational diabetes\nthe IMPACT of Vitamin D on vascular health and Glucose Control CAN LIKEWISE TRANSLATE to adverse EFFECTS of Vitamin D deficiency on Pregnancy outcomes including an INCREASED risk for Gestational diabetes and Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 88), ('SUPERFICIAL_RELATIONSHIP', 97), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 185)]	6	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_28384', 'vitamin K', 35, 'Vitamin D'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0046323', 'glucose import', 68, 'glucose control'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'gestational'), ('GO_0007128', 'meiotic prophase I', 229, 'preeclampsia')]
S111-PMC4934634	PMC4934634	11/2015	S111-PMC4934634	['the THEORY that Vitamin D supplementation CAN help normalize Blood Glucose levels and reduce the incidence of Gestational diabetes is an active AREA of research.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 42), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0007565', 'female pregnancy', 110, 'gestational')]
S116-PMC4934634	PMC4934634	11/2015	S116-PMC4934634	['the EFFECTS of Vitamin D supplementation (400 iu /day Vitamin D3) on Insulin and Glucose Metabolism were observed in healthy, Pregnant women in their 25th week of Gestation [45].']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 54, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 54, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 69, 'insulin ...'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('GO_0006006', 'glucose metabolic process', 81, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]
S122-PMC4934634	PMC4934634	11/2015	S122-PMC4934634	['improved Serum Insulin, Insulin resistance index (homa-ir), fasting Plasma Glucose, ldl and total Cholesterol were NOTED in the Vitamin D group compared to the placebo group.']	[('ANOMALY_CURIOUS_FINDING', 115)]	1	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('PR_000045358', 'insulin family protein', 15, 'insulin'), ('PR_000045358', 'insulin family protein', 24, 'insulin'), ('UBERON_0001969', 'blood plasma', 68, 'plasma'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('CHEBI_16113', 'cholesterol', 98, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
S129-PMC4934634	PMC4934634	11/2015	S129-PMC4934634	['IN AGREEMENT WITH ANOTHER STUDY by the same group [45], Vitamin D plus calcium supplementation improved fasting Plasma Glucose, serum Insulin, homa-ir, hdl, and ldl in women with Gestational diabetes compared TO placebo.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 209)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 112, 'plasma'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('PR_000045358', 'insulin family protein', 134, 'insulin'), ('GO_0007565', 'female pregnancy', 179, 'gestational')]
S133-PMC4934634	PMC4934634	11/2015	S133-PMC4934634	['to test the dose response EFFECT of Vitamin D on Glucose Metabolism, doses of 200 iu/day, 50,000 iu/monthly, or 50,000 iu/biweekly Vitamin D3Were chosen to supplement healthy (non-Gestational diabetes), Pregnant women with severe Vitamin D deficiency (7.6 ± 6.3 ng/ml) from the 12th week of Gestation to Delivery [49].']	[('SUPERFICIAL_RELATIONSHIP', 26)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0006006', 'glucose metabolic process', 49, 'glucose metabolism'), ('CHEBI_73706', 'bromosuccinate', 131, 'vitamin D3were'), ('PR_000017209', 'utrophin', 131, 'vitamin D3were'), ('GO_0007565', 'female pregnancy', 180, 'gestational'), ('GO_0007565', 'female pregnancy', 203, 'pregnant'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'gestation'), ('GO_0007567', 'parturition', 304, 'delivery')]
S15-PMC4944244	PMC4944244	7/2016	S15-PMC4944244	['lack of Vitamin D MAY have an adverse health EFFECTS including death, cancer, Cardiovascular disease, impaired Immune function and Glucose Metabolism [4].']	[('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 45)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 78, 'cardiovascular'), ('UBERON_0002405', 'immune system', 111, 'immune'), ('CHEBI_17234', 'glucose', 131, 'glucose'), ('GO_0006006', 'glucose metabolic process', 131, 'glucose metabolism')]
S80-PMC5030591	PMC5030591	9/2016	S80-PMC5030591	"[""caption (table-wrap): table 4\n\nthemes and elements relating to specific Conception and Pregnancy information for women with rheumatoid arthritis and their familiessaying : information that should be discussed by health professionals doing : actions that SHOULD BE undertaken by health professionals review of current Medications in relation to safety during Conception and Pregnancy (100%) prior to Conception and Pregnancy, review current Medication(s) and discuss:\nmedications vary with respect to their SAFETY during Pregnancy and RISKS related to Fertility, Ovulation, Conception and Miscarriage\nSOME Medicines used in ra care MAY have EFFECTS on Fertility, Conception and Pregnancy process, for example, regular Nsaids MAY impair fertility and ASSOCIATED RISKS with fetus\nit is IMPORTANT to time Conceptionprovide GUIDANCE as to WHERE to obtain reliable information about SAFETY of Medicines in Pregnancywhere current Medication(s) is (are) contraindicated for Conception/Pregnancy the following SHOULD BE discussed with the patient:\nthere are SAFE Medication options pre, during (including Delivery) and Postpregnancy (including Breast feeding)\ntiming is IMPORTANT in RELATION to ceasing or switching of current Medications and allowing for washout periods prior to Conception\nthere is a need for close supervision/monitoring by a rheumatologist when discontinuing current Medications prior to Pregnancy, including CONSIDERING POTENTIAL NEED for disease stabilisation on new treatment prior to Conception and Pregnancydiscuss IMPACT of ra pathology on Pregnancy and Pregnancy on ra (100%) there are DIFFERENT SCENARIOS regarding ra disease activity during Pregnancy (eg, POSSIBLE remission/low disease activity)discuss: ra-related pain management options during Pregnancyconception MAY take longer compared with women who do not have rathere is a need to balance disease Control with maternal and fetal health and safetyra MAY AFFECT Pregnancy and Pregnancy MAY AFFECT ra, and there are POSSIBLE adverse outcomes where risks are identified (eg, Prematurity)there are significant risks ASSOCIATED with active or uncontrolled ra for the mother and baby, ESPECIALLY irreversible Joint damage and functional impairmentpregnancy MAY change a patient’s health outlook in the futurethe size of the baby MAY BE smaller than women without ra and MAY also be Delivered pre-term discuss IMPORTANT elements of Preconception care RELEVANT to patient (97.1%) it is IMPORTANT to achieve optimal disease control prior to considering Pregnancy—Planning Conception is preferable after patients achieve and maintain low disease activityencourage and facilitate early discussions with all health practitioners involved in care about family planning to allow for adequate preparationthere is a CRITICAL need for a planned Pregnancy RATHER than an unplanned Pregnancyreview Prenatal nutrition, including need for dietary/vitamin supplements (ie, Folic Acid, calcium, Vitamin D, Iodine, iron)history of previous Attempts To Conceive/Pregnancies or Pregnancy-related complications (eg, Miscarriage) and other relevant patient history (such as smoking/Illicit Drug use history, family history of hereditary issues) MAY AFFECT Pregnancyundertake RELEVANT health checks such as immunisation status (eg, rubella, varicella, pertussis), Sexually Transmitted disease screening, pap test, screening for other Autoimmune disorders that MAY IMPACT on Pregnancyweight management and appropriate exercise are very IMPORTANTCONSIDER the NEED for review of diabetes or impaired Glucose tolerance if RISK factors are present (eg, on Steroid medication or overweight/obese)it is IMPORTANT to manage comorbid conditions, such as diabetes and hypertensionsome women MAY NEED to avoid Conception during a flarera disease activity MAY or MAY not improve with Pregnancy and there is a LIKELIHOOD of Postpartum flares importance of maintaining optimistic outlook and providing positive messages (97.1%) Pregnancy and Breast feeding success rates are near normal in women with mild to moderate ra nowadays (where appropriate for the patient's clinical status)ra is not a BARRIER to Pregnancystrategies to address anxiety, stress and depression (if relevant) are IMPORTANT, such as mindfulness meditation need for close monitoring of a patient prior to and during Pregnancy, where indicated (94.1%) it is IMPORTANCE to have a healthcare team with expertise in Autoimmune disorders for SOME women with radetermine THE NEED for high-level obstetric care during a Pregnancy (where indicated), including the need for Anaesthetic inputsome women REQUIRE closer monitoring of their Pregnancy and this is USUALLY proportional to disease activity, comorbidities and maternal historyassess the REQUIREMENTS for any extra treatment or monitoring prior to, or during, Pregnancyit is IMPORTANT to develop a Pregnancy plan, which includes different options for management of ra and support for different scenariosvaginal Delivery MAY NOT always BE POSSIBLE, depending on condition of the patient's Hips.""]"	[('FUTURE_WORK', 254), ('IMPORTANT_CONSIDERATION', 506), ('IMPORTANT_CONSIDERATION', 534), ('INCOMPLETE_EVIDENCE', 600), ('INCOMPLETE_EVIDENCE', 631), ('SUPERFICIAL_RELATIONSHIP', 640), ('INCOMPLETE_EVIDENCE', 724), ('SUPERFICIAL_RELATIONSHIP', 749), ('IMPORTANT_CONSIDERATION', 760), ('IMPORTANT_CONSIDERATION', 783), ('FUTURE_WORK', 819), ('EXPLICIT_QUESTION', 834), ('IMPORTANT_CONSIDERATION', 877), ('FUTURE_WORK', 1001), ('IMPORTANT_CONSIDERATION', 1049), ('IMPORTANT_CONSIDERATION', 1161), ('SUPERFICIAL_RELATIONSHIP', 1174), ('FUTURE_WORK', 1421), ('IMPORTANT_CONSIDERATION', 1421), ('INCOMPLETE_EVIDENCE', 1433), ('SUPERFICIAL_RELATIONSHIP', 1532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1605), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('INCOMPLETE_EVIDENCE', 1677), ('INCOMPLETE_EVIDENCE', 1788), ('INCOMPLETE_EVIDENCE', 1929), ('SUPERFICIAL_RELATIONSHIP', 1933), ('INCOMPLETE_EVIDENCE', 1964), ('SUPERFICIAL_RELATIONSHIP', 1968), ('INCOMPLETE_EVIDENCE', 1993), ('SUPERFICIAL_RELATIONSHIP', 2091), ('IMPORTANT_CONSIDERATION', 2158), ('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2302), ('INCOMPLETE_EVIDENCE', 2343), ('IMPORTANT_CONSIDERATION', 2382), ('SUPERFICIAL_RELATIONSHIP', 2423), ('IMPORTANT_CONSIDERATION', 2457), ('IMPORTANT_CONSIDERATION', 2779), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2817), ('INCOMPLETE_EVIDENCE', 3196), ('SUPERFICIAL_RELATIONSHIP', 3200), ('IMPORTANT_CONSIDERATION', 3226), ('INCOMPLETE_EVIDENCE', 3410), ('SUPERFICIAL_RELATIONSHIP', 3414), ('IMPORTANT_CONSIDERATION', 3485), ('INCOMPLETE_EVIDENCE', 3507), ('SUPERFICIAL_RELATIONSHIP', 3568), ('IMPORTANT_CONSIDERATION', 3646), ('INCOMPLETE_EVIDENCE', 3731), ('FUTURE_WORK', 3735), ('IMPORTANT_CONSIDERATION', 3735), ('INCOMPLETE_EVIDENCE', 3794), ('INCOMPLETE_EVIDENCE', 3801), ('PROBABLE_UNDERSTANDING', 3847), ('DIFFICULT_TASK', 4131), ('IMPORTANT_CONSIDERATION', 4222), ('IMPORTANT_CONSIDERATION', 4364), ('INCOMPLETE_EVIDENCE', 4444), ('INCOMPLETE_EVIDENCE', 4472), ('IMPORTANT_CONSIDERATION', 4600), ('INCOMPLETE_EVIDENCE', 4657), ('IMPORTANT_CONSIDERATION', 4744), ('IMPORTANT_CONSIDERATION', 4831), ('INCOMPLETE_EVIDENCE', 4976), ('DIFFICULT_TASK', 4980)]	66	[('GO_0007631', 'feeding behavior', 72, 'conception ...'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_25441', 'mycothiols', 317, 'medications'), ('GO_0007620', 'copulation', 358, 'conception'), ('GO_0007565', 'female pregnancy', 373, 'pregnancy'), ('GO_0007620', 'copulation', 399, 'conception'), ('GO_0007565', 'female pregnancy', 414, 'pregnancy'), ('CHEBI_60211', 'compound Z', 440, 'medication'), ('GO_0007565', 'female pregnancy', 520, 'pregnancy'), ('GO_0009566', 'fertilization', 551, 'fertility'), ('GO_0030728', 'ovulation', 562, 'ovulation'), ('GO_0007620', 'copulation', 573, 'conception'), ('GO_0046660', 'female sex differentiation', 588, 'miscarriage'), ('CHEBI_25179', 'melanins', 605, 'medicines'), ('GO_0009566', 'fertilization', 651, 'fertility'), ('GO_0007620', 'copulation', 662, 'conception'), ('GO_0007565', 'female pregnancy', 677, 'pregnancy'), ('CHEBI_16039', 'ITP', 717, 'NSAIDs'), ('GO_0070268', 'cornification', 801, 'conceptionProvide'), ('CHEBI_25179', 'melanins', 887, 'medicines'), ('GO_0000712', 'resolution of meiotic recombination intermediates', 900, 'pregnancyWhere'), ('CHEBI_60211', 'compound Z', 923, 'medication'), ('GO_0007620', 'copulation', 966, 'conception'), ('GO_0007565', 'female pregnancy', 977, 'pregnancy'), ('CHEBI_60211', 'compound Z', 1054, 'medication'), ('GO_0007567', 'parturition', 1096, 'delivery'), ('GO_0007565', 'female pregnancy', 1110, 'postpregnancy'), ('UBERON_0000310', 'breast', 1135, 'breast'), ('CHEBI_25441', 'mycothiols', 1218, 'medications'), ('GO_0007620', 'copulation', 1272, 'conception'), ('CHEBI_25441', 'mycothiols', 1379, 'medications'), ('GO_0007565', 'female pregnancy', 1400, 'pregnancy'), ('GO_0007620', 'copulation', 1500, 'conception'), ('GO_0006915', 'apoptotic process', 1515, 'pregnancyDiscuss'), ('GO_0007565', 'female pregnancy', 1558, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1572, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1662, 'pregnancy'), ('GO_0007602', 'phototransduction', 1768, 'pregnancyConception'), ('GO_0065007', 'biological regulation', 1877, 'control'), ('GO_0007565', 'female pregnancy', 1940, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1954, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2051, 'prematurity'), ('UBERON_0004905', 'articulation', 2182, 'joint'), ('GO_0007567', 'parturition', 2355, 'delivered'), ('GO_0007565', 'female pregnancy', 2404, 'preconception'), ('GO_0007565', 'female pregnancy', 2523, 'pregnancy'), ('GO_0006260', 'DNA replication', 2533, 'planning'), ('GO_0007620', 'copulation', 2542, 'conception'), ('GO_0007565', 'female pregnancy', 2807, 'pregnancy'), ('GO_0006412', 'translation', 2842, 'pregnancyReview'), ('GO_0007565', 'female pregnancy', 2858, 'prenatal'), ('CHEBI_30751', 'formic acid', 2930, 'folic acid'), ('CHEBI_27300', 'vitamin D', 2951, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 2962, 'iodine'), ('GO_0000380', 'alternative mRNA splicing, via spliceosome', 2995, 'attempts to conceive'), ('GO_0007565', 'female pregnancy', 3016, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3031, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3068, 'miscarriage'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 3133, 'illicit drug'), ('GO_0051610', 'serotonin uptake', 3207, 'pregnancyUndertake'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 3314, 'sexually transmitted'), ('UBERON_0001442', 'skeleton of manus', 3384, 'autoimmune'), ('GO_0006412', 'translation', 3424, 'pregnancyWeight'), ('CHEBI_17234', 'glucose', 3547, 'glucose'), ('CHEBI_35341', 'steroid', 3601, 'steroid'), ('GO_0007620', 'copulation', 3749, 'conception'), ('GO_0007565', 'female pregnancy', 3822, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3861, 'postpartum'), ('GO_0007565', 'female pregnancy', 3964, 'Pregnancy'), ('UBERON_0000310', 'breast', 3978, 'breast'), ('GO_0006915', 'apoptotic process', 4142, 'pregnancyStrategies'), ('GO_0007565', 'female pregnancy', 4323, 'pregnancy'), ('UBERON_0001442', 'skeleton of manus', 4419, 'autoimmune'), ('GO_0007565', 'female pregnancy', 4520, 'pregnancy'), ('CHEBI_38867', 'anaesthetic', 4572, 'anaesthetic'), ('GO_0007565', 'female pregnancy', 4635, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4816, 'pregnancyIt'), ('GO_0007565', 'female pregnancy', 4854, 'pregnancy'), ('GO_0007567', 'parturition', 4967, 'delivery'), ('UBERON_0000988', 'pons', 5044, 'hips')]
S9-PMC5035678	PMC5035678	4/2016	S9-PMC5035678	['conclusions\nALTHOUGH the high Vitamin D supplementation dose in the PRESENT STUDY (compared to the 400 iu/day dose USUALLY recommended for Pregnancy) SAFELY increases the Serum 25Ohd, in gdm cases, the higher dose does not affect the plasma Glucose level or Insulin resistance at short term follow-up after Delivery.']	[('ANOMALY_CURIOUS_FINDING', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 150)]	4	"[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 177, '25OHD'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007567', 'parturition', 307, 'delivery')]"
S19-PMC5035678	PMC5035678	4/2016	S19-PMC5035678	['an inverse RELATIONSHIP between serum Vitamin D levels and Glucose Metabolism in women with gdm HAS BEEN REPORTED in several observational studies (8-11).']	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 96)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('GO_0006006', 'glucose metabolic process', 59, 'glucose metabolism')]
S26-PMC5035678	PMC5035678	4/2016	S26-PMC5035678	['objectives\nwe THEREFORE SOUGHT TO EXPLORE the EFFECT of Vitamin D supplementation in women with gdm and hypovitaminosis D, both on post-Partum Glucose levels and Insulin resistance, in a randomized clinical trial.']	[('PROBABLE_UNDERSTANDING', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 46)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('GO_0007567', 'parturition', 136, 'partum'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('PR_000045358', 'insulin family protein', 162, 'insulin')]
S109-PMC5035678	PMC5035678	4/2016	S109-PMC5035678	['discussion\nTO OUR KNOWLEDGE, THIS is the FIRST STUDY TO EVALUATE the EFFECTS of Vitamin D supplementation during Pregnancy on Glucose Metabolism shortly after Delivery.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('INCOMPLETE_EVIDENCE', 41), ('QUESTION_ANSWERED_BY_THIS_WORK', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 53), ('SUPERFICIAL_RELATIONSHIP', 69)]	6	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0006006', 'glucose metabolic process', 126, 'glucose metabolism'), ('GO_0007567', 'parturition', 159, 'delivery')]
S110-PMC5035678	PMC5035678	4/2016	S110-PMC5035678	['OUR STUDY DEMONSTRATES that high dose Vitamin D supplementation during Pregnancy in women with gdm and impairment of 25Ohd concentration has no effect on post-Partum Plasma Glucose and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10)]	2	"[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 117, '25OHD'), ('GO_0007567', 'parturition', 159, 'partum'), ('UBERON_0001969', 'blood plasma', 166, 'plasma'), ('CHEBI_17234', 'glucose', 173, 'glucose'), ('PR_000045358', 'insulin family protein', 185, 'insulin')]"
S115-PMC5035678	PMC5035678	4/2016	S115-PMC5035678	['HOWEVER, there is SCARCE INFORMATION about the EFFECT of Vitamin D supplementation on Glucose Metabolism, especially during Pregnancy and after Delivery.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 47)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('GO_0006006', 'glucose metabolic process', 86, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007567', 'parturition', 144, 'delivery')]
S132-PMC5035678	PMC5035678	4/2016	S132-PMC5035678	['they FOUND that high dose supplementation for a mean of 14 weeks during Pregnancy was not beneficial to the patients’ plasma Glucose level or Insulin resistance during Pregnancy, BUT that their babies BENEFITTED from the supplementation with decreased neonatal hypovitaminosis D. the authors CONCLUDED that the commencement of Vitamin D supplementation MAY HAVE been too late to cause any observable EFFECTS on Β-Cell function, and they SUGGESTED that earlier supplementation, EVEN before Pregnancy, MIGHT be EFFECTIVE.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('IMPORTANT_CONSIDERATION', 201), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 353), ('IMPORTANT_CONSIDERATION', 357), ('SUPERFICIAL_RELATIONSHIP', 400), ('INCOMPLETE_EVIDENCE', 437), ('ANOMALY_CURIOUS_FINDING', 477), ('INCOMPLETE_EVIDENCE', 500), ('SUPERFICIAL_RELATIONSHIP', 509)]	11	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 142, 'insulin'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CL_0000623', 'natural killer cell', 411, 'β-cell'), ('GO_0007565', 'female pregnancy', 489, 'pregnancy')]
S133-PMC5035678	PMC5035678	4/2016	S133-PMC5035678	['in OUR STUDY, over a median interval of 26 weeks between commencement of Vitamin D supplements and ogtt measurements, high dose Vitamin D LED TO maternal and neonatal 25Ohd level increases, but not to the predicted EFFECTS on Glucose level and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 215)]	3	"[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 167, '25OHD'), ('CHEBI_17234', 'glucose', 226, 'glucose'), ('PR_000045358', 'insulin family protein', 244, 'insulin')]"
S143-PMC5035678	PMC5035678	4/2016	S143-PMC5035678	['in ANOTHER STUDY of the non-Pregnant population, and CONSISTENT with our results, davidson and colleagues FOUND that a mean supplement dose of 88,865 iu Vitamin D per week, in 56 subjects with hypovitaminosis D and pre-diabetes, had no effect on Insulin resistance and plasma Glucose levels at 3, 6, 9, and 12 months after intervention, compared to 53 subjects in a placebo group (31).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 106)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'D'), ('PR_000045358', 'insulin family protein', 246, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose')]
S147-PMC5035678	PMC5035678	4/2016	S147-PMC5035678	['as PREVIOUSLY discussed, a LIMITED NUMBER OF STUDIES have evaluated the EFFECT of Vitamin D on Glucose Metabolism and Insulin resistance, especially during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]
S121-PMC5085625	PMC5085625	9/2016	S121-PMC5085625	['furthermore, a direct LINK between Glucose Metabolism and Vitamin D pathways HAS BEEN identified.']	[('SUPERFICIAL_RELATIONSHIP', 22), ('INCOMPLETE_EVIDENCE', 77)]	2	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('GO_0006006', 'glucose metabolic process', 35, 'glucose metabolism'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
S126-PMC5085625	PMC5085625	9/2016	S126-PMC5085625	['to summarize, the LINK between Vitamin D and Glucose Metabolism REQUIRES FURTHER STUDIES on larger populations of Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('IMPORTANT_CONSIDERATION', 64), ('FUTURE_WORK', 73)]	3	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0006006', 'glucose metabolic process', 45, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 114, 'pregnant')]
S154-PMC5100620	PMC5100620	10/2016	S154-PMC5100620	['no such effects on Lipids were FOUND in the nepal trial that included multiple Micronutrient supplements and allocated Vitamin A only as control.19\n\nGlucose Metabolism\nchildren of mothers receiving mms had significantly lower fasting Glucose levels as compared with those allocated to the standard fe60f.']	[('INCOMPLETE_EVIDENCE', 31)]	1	[('CHEBI_18059', 'lipid', 19, 'lipids'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 79, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('CHEBI_17234', 'glucose', 149, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 149, 'Glucose metabolism'), ('CHEBI_17234', 'glucose', 234, 'glucose')]
S14-PMC5115165	PMC5115165	1/2016	S14-PMC5115165	['introduction\npotatoes are the third most commonly Consumed Food crop in the world, after rice and wheat.1in the united states, about 35% of women of Reproductive Age (that is, aged 19-50) Consume potatoes daily, accounting FOR 8% of daily total energy intake.2the health EFFECTS of potatoes are INCONCLUSIVE,13and there HAVE BEEN longstanding DEBATES on the appropriate placement of potatoes in dietary guidance.456nonetheless, the dietary guidelines for americans continue to include potatoes in the vegetable Food group and encourage Consumption.7THOUGH potatoes are rich in Vitamin C, Potassium, dietary fiber, and some Phytochemicals,6unlike other vegetables they CAN have DETRIMENTAL EFFECTS on Glucose Metabolism because they contain large amounts of rapidly absorbable Starch.3indeed, SEVERAL epidemiologic STUDIES have LINKED higher potato Consumption to increased concentrations of fasting Plasma Glucose,8insulin resistance,8and an increased risk of type 2 diabetes mellitus.910\nGestational diabetes mellitus (gdm) is a common COMPLICATION of Pregnancy characterized by Glucose intolerance with onset or first recognition during Pregnancy.11gdm is not only ASSOCIATED with adverse Perinatal outcomes,12it is also RELATED to increased long term Cardiometabolic risk in both mothers and their offspring.1113it is THEREFORE CRUCIAL to identify modifiable RISK FACTORS that COULD CONTRIBUTE to the PREVENTION of gdm.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 223), ('SUPERFICIAL_RELATIONSHIP', 271), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 295), ('INCOMPLETE_EVIDENCE', 320), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 343), ('ANOMALY_CURIOUS_FINDING', 548), ('INCOMPLETE_EVIDENCE', 668), ('IMPORTANT_CONSIDERATION', 677), ('SUPERFICIAL_RELATIONSHIP', 689), ('INCOMPLETE_EVIDENCE', 792), ('SUPERFICIAL_RELATIONSHIP', 827), ('PROBLEM_COMPLICATION', 1037), ('SUPERFICIAL_RELATIONSHIP', 1167), ('SUPERFICIAL_RELATIONSHIP', 1223), ('PROBABLE_UNDERSTANDING', 1321), ('IMPORTANT_CONSIDERATION', 1331), ('SUPERFICIAL_RELATIONSHIP', 1362), ('INCOMPLETE_EVIDENCE', 1380), ('SUPERFICIAL_RELATIONSHIP', 1386), ('SUPERFICIAL_RELATIONSHIP', 1404)]	20	[('GO_0007631', 'feeding behavior', 50, 'consumed'), ('CHEBI_33290', 'food', 59, 'food'), ('GO_0000003', 'reproduction', 149, 'reproductive age'), ('GO_0007631', 'feeding behavior', 188, 'consume'), ('CHEBI_33290', 'food', 511, 'food'), ('GO_0007631', 'feeding behavior', 536, 'consumption'), ('CHEBI_27300', 'vitamin D', 577, 'vitamin C'), ('CHEBI_22314', 'alkali metal atom', 588, 'potassium'), ('CHEBI_26254', 'prenylnaphthoquinone', 623, 'phytochemicals'), ('CHEBI_17234', 'glucose', 700, 'glucose'), ('GO_0006006', 'glucose metabolic process', 700, 'glucose metabolism'), ('CHEBI_28017', 'starch', 776, 'starch'), ('GO_0007631', 'feeding behavior', 848, 'consumption'), ('UBERON_0001969', 'blood plasma', 899, 'plasma'), ('CHEBI_17234', 'glucose', 906, 'glucose'), ('GO_0007565', 'female pregnancy', 989, 'Gestational'), ('GO_0007565', 'female pregnancy', 1053, 'pregnancy'), ('CHEBI_17234', 'glucose', 1080, 'glucose'), ('GO_0007565', 'female pregnancy', 1139, 'pregnancy'), ('GO_0036268', 'swimming', 1191, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1191, 'perinatal'), ('GO_0007599', 'hemostasis', 1254, 'cardiometabolic')]
S53-PMC5332602	PMC5332602	3/2017	S53-PMC5332602	['the normal ranges of the levels of these elements in the Plasma or Serum of conventional Suckling Piglets are 44 to 91\xa0mg/dl for Glucose, 5.8 to 8.1\xa0g/dl for protein, 3.2 to 4.2\xa0g/dl for Albumin, 100 to 350\xa0ng/ml for Vitamin A, 0.4 to 5\xa0μg/ml for Vitamin E, and 50 to 150\xa0ng/ml for Selenium; HOWEVER, the respective ranges in gn Pigs are NOT ESTABLISHED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 292), ('ANOMALY_CURIOUS_FINDING', 292), ('FULL_UNKNOWN', 338)]	3	[('UBERON_0001969', 'blood plasma', 57, 'plasma'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('GO_0001967', 'suckling behavior', 89, 'suckling'), ('NCBITaxon_33208', 'Metazoa', 98, 'piglets'), ('CHEBI_17234', 'glucose', 129, 'glucose'), ('PR_000005908', 'alpha-crystallin B chain', 187, 'albumin'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 282, 'selenium'), ('NCBITaxon_10088', 'Mus <genus>', 329, 'pigs')]
S180-PMC5332602	PMC5332602	3/2017	S180-PMC5332602	['in addition to decreased Serum protein, Albumin, and Glucose levels, we observed that protein malnutrition AFFECTED the Homeostatic Control of Selenium and Vitamins A and e, CONSISTENT with SIMILAR observations on secondary Micronutrient deficiencies ASSOCIATED with childhood malnourishment (1).']	[('SUPERFICIAL_RELATIONSHIP', 107), ('INCOMPLETE_EVIDENCE', 174), ('INCOMPLETE_EVIDENCE', 190), ('SUPERFICIAL_RELATIONSHIP', 251)]	4	[('UBERON_0001977', 'blood serum', 25, 'serum'), ('PR_000005908', 'alpha-crystallin B chain', 40, 'albumin'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042592', 'homeostatic process', 120, 'homeostatic'), ('GO_0065007', 'biological regulation', 132, 'control'), ('CHEBI_27568', 'selenium atom', 143, 'selenium'), ('GO_0007601', 'visual perception', 143, 'selenium'), ('CHEBI_27300', 'vitamin D', 156, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 156, 'vitamins A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 224, 'micronutrient')]
S233-PMC5332602	PMC5332602	3/2017	S233-PMC5332602	['Serum samples collected at the end of the experiment were submitted to marshfield labs (marshfield, wi) and the diagnostic center for population and Animal health (michigan state university, east lansing, mi) TO ASSESS levels of protein/albumin/Glucose and Vitamin A/Vitamin E/Selenium, respectively.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 209)]	1	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('NCBITaxon_33208', 'Metazoa', 149, 'Animal'), ('CHEBI_17234', 'glucose', 245, 'glucose'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 277, 'selenium')]
S53-PMC5359891	PMC5359891	3/2017	S53-PMC5359891	['taken TOGETHER, there is strong SUPPORT for NEW intervention studies commencing before Pregnancy to provide myo-inositol and Probiotics, and to improve maternal Vitamin B6, Vitamin B12, Vitamin D and zinc status, AIMED at optimising maternal glycaemia and Glucose supply to the Feto-Placental Unit to promote healthy offspring growth and body composition.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 44), ('QUESTION_ANSWERED_BY_THIS_WORK', 213)]	4	[('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_26346', 'prostaglandins J', 125, 'probiotics'), ('CHEBI_33237', 'vitamin D4', 161, 'vitamin B6'), ('CHEBI_33229', 'vitamin (role)', 173, 'vitamin'), ('CHEBI_27778', 'abequose', 181, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 181, 'B12'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_17234', 'glucose', 256, 'glucose'), ('UBERON_0000981', 'femur', 278, 'feto'), ('UBERON_0013765', 'digestive system element', 283, 'placental unit')]
S92-PMC5359891	PMC5359891	3/2017	S92-PMC5359891	['the intervention\nthe nutritional intervention Preconception and during Pregnancy to maintain healthy Glucose Metabolism and offspring health (nipper) intervention comprises: (1) a Micronutrient-enriched nutritional drink containing myo-inositol, Vitamin D, riboflavin, Vitamin B6, Vitamin B12And zinc together with standard Folic Acid, Iodine, calcium, β-Carotene and iron; the quantities PROPOSED are either standard amounts (Myo-Inositol [54]), enhanced amounts that are available in over-the-counter products (Vitamins b6, b12, riboflavin), RECOMMENDED daily allowance amounts in uk for Pregnant women (Vitamin D, zinc, Folic Acid, Iodine) or minimal amounts for Micronutrients LINKED with POTENTIAL DETRIMENTAL EFFECTS at higher doses (Iron, Β-Carotene, Calcium) and (2) Probiotics (containing lactobacillus rhamnosus ncc 4007 (cgmcc 1.3724) also known as lpr and bifidobacterium animalis Sp.']	[('INCOMPLETE_EVIDENCE', 389), ('FUTURE_WORK', 544), ('SUPERFICIAL_RELATIONSHIP', 681), ('INCOMPLETE_EVIDENCE', 693), ('IMPORTANT_CONSIDERATION', 703), ('SUPERFICIAL_RELATIONSHIP', 715)]	6	[('GO_0007565', 'female pregnancy', 46, 'Preconception'), ('GO_0007565', 'female pregnancy', 71, 'Pregnancy'), ('CHEBI_17234', 'glucose', 101, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 101, 'Glucose Metabolism'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 180, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 269, 'vitamin B6'), ('CHEBI_10124', 'zolmitriptan', 281, 'vitamin B12and'), ('CHEBI_30751', 'formic acid', 324, 'folic acid'), ('CHEBI_24859', 'iodine atom', 336, 'iodine'), ('CHEBI_23042', 'carotene', 355, 'carotene'), ('CHEBI_25435', 'mutagen', 427, 'myo-inositol'), ('CHEBI_33277', 'gamma-tocotrienol', 513, 'vitamins'), ('GO_0007565', 'female pregnancy', 590, 'pregnant'), ('CHEBI_27300', 'vitamin D', 606, 'vitamin D'), ('CHEBI_30751', 'formic acid', 623, 'folic acid'), ('CHEBI_24859', 'iodine atom', 635, 'iodine'), ('CHEBI_33839', 'macromolecule', 666, 'micronutrients'), ('CHEBI_24870', 'ion', 740, 'iron'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 746, 'β-carotene'), ('CHEBI_22313', 'alkaline earth metal atom', 758, 'calcium'), ('CHEBI_26346', 'prostaglandins J', 775, 'probiotics'), ('NCBITaxon_10088', 'Mus <genus>', 893, 'sp')]
S108-PMC5359891	PMC5359891	3/2017	S108-PMC5359891	['omission from control group SUPPORTED by usual clinical practiceβ-Carotene720\xa0μg (15% of Vitamin A REQUIREMENTS, as Retinol equivalents)required in Pregnancy in some jurisdictionsfolic acid400\xa0μgstandard Preconception RECOMMENDATIONIRON12\xa0mgiron is routinely prescribed and taken before/during Pregnancy, THOUGH WITHOUT CONVINCING EVIDENCE of benefit; low dose included to lessen LIKELIHOOD of additionally receiving a high-dose iron product, which HAS BEEN LINKED with Glucose Metabolism in Pregnancycalcium150\xa0mga low dose of Calcium is commonly taken before/during Pregnancy; provision of this will lessen the LIKELIHOOD of additional products being takeniodine150\xa0μgstandard preconception recommendationprobiotictaking a combination of two Probiotics HAS BEEN LINKED with maintenance of healthy Glucose Metabolism in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 99), ('FUTURE_WORK', 218), ('ANOMALY_CURIOUS_FINDING', 305), ('INCOMPLETE_EVIDENCE', 312), ('PROBABLE_UNDERSTANDING', 380), ('INCOMPLETE_EVIDENCE', 449), ('SUPERFICIAL_RELATIONSHIP', 458), ('PROBABLE_UNDERSTANDING', 613), ('INCOMPLETE_EVIDENCE', 755), ('SUPERFICIAL_RELATIONSHIP', 764)]	11	[('CHEBI_85000', '1-octadecenoyl-2-icosatetraenoyl-sn-glycero-3-phosphoethanolamine', 65, '-carotene720'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 116, 'retinol'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'preconception'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy'), ('CHEBI_17234', 'glucose', 470, 'glucose'), ('GO_0006006', 'glucose metabolic process', 470, 'glucose metabolism'), ('GO_0051561', 'positive regulation of mitochondrial calcium ion concentration', 492, 'pregnancyCalcium150'), ('CHEBI_22313', 'alkaline earth metal atom', 528, 'calcium'), ('GO_0007565', 'female pregnancy', 568, 'pregnancy'), ('CHEBI_26346', 'prostaglandins J', 744, 'probiotics'), ('CHEBI_17234', 'glucose', 799, 'glucose'), ('GO_0006006', 'glucose metabolic process', 799, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 821, 'pregnancy')]
S110-PMC5359891	PMC5359891	3/2017	S110-PMC5359891	['lactis ncc 2818 (cncm i-3446) also known as bl818control groupfolic Acid400\xa0μgstandard Preconception recommendationiron12\xa0mgiron is routinely prescribed and taken before/during Pregnancy, though WITHOUT CONVINCING EVIDENCE of benefit; low dose included to lessen LIKELIHOOD of additionally receiving a high-dose Iron product, which HAS BEEN LINKED with Glucose Metabolism in Pregnancycalcium150\xa0mga low dose of Calcium is commonly taken before/during Pregnancy; provision of this will lessen the LIKELIHOOD of additional products being takeniodine150\xa0μgstandard Preconception recommendationhttp://www.cdc.gov/Preconception/documents/clinical-content_womensnutritionfactsheet3.pdfβ-Carotene720\xa0μg (15% of Vitamin A REQUIREMENTS, as Retinol equivalents)required in Pregnancy in some jurisdictions\n\noutcome measurements\nthe primary analysis will adjust for site, ethnicity and Preconception glycaemia to account for POTENTIAL imbalance between treatment arms amongst Pregnancies which reach 28\xa0weeks’ Gestation, examining for differences in means between the control and intervention groups for the primary endpoint, specifically the fasting and/or 60-min and/or 2-h Glucose concentrations following a 75-g ogtt at 28\xa0weeks’ Gestation.']	[('INCOMPLETE_EVIDENCE', 195), ('PROBABLE_UNDERSTANDING', 263), ('INCOMPLETE_EVIDENCE', 332), ('SUPERFICIAL_RELATIONSHIP', 341), ('PROBABLE_UNDERSTANDING', 496), ('IMPORTANT_CONSIDERATION', 714), ('INCOMPLETE_EVIDENCE', 913)]	7	"[('CHEBI_82451', ""3,3'-Dimethoxybenzidine-4,4'-diisocyanate"", 68, 'acid400'), ('GO_0007565', 'female pregnancy', 87, 'preconception'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy'), ('CHEBI_24870', 'ion', 312, 'iron'), ('CHEBI_17234', 'glucose', 353, 'glucose'), ('GO_0006006', 'glucose metabolic process', 353, 'glucose metabolism'), ('GO_0051561', 'positive regulation of mitochondrial calcium ion concentration', 375, 'pregnancyCalcium150'), ('CHEBI_22313', 'alkaline earth metal atom', 411, 'calcium'), ('GO_0007565', 'female pregnancy', 451, 'pregnancy'), ('GO_0007565', 'female pregnancy', 562, 'preconception'), ('GO_0007565', 'female pregnancy', 609, 'preconception'), ('CHEBI_52743', 'bromine-79 atom', 681, 'carotene720'), ('CHEBI_27300', 'vitamin D', 704, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 731, 'retinol'), ('GO_0007565', 'female pregnancy', 763, 'pregnancy'), ('GO_0007565', 'female pregnancy', 874, 'preconception'), ('GO_0007565', 'female pregnancy', 964, 'pregnancies'), ('GO_0007565', 'female pregnancy', 998, 'gestation'), ('CHEBI_17234', 'glucose', 1164, 'glucose'), ('GO_0007565', 'female pregnancy', 1222, 'gestation')]"
S112-PMC5359891	PMC5359891	3/2017	S112-PMC5359891	['secondary maternal outcomes of the initial phase of the nipper study are:\nmaintenance of a healthy Pregnancy, including normal duration of Gestation (at least 37\xa0weeks’ Gestation), absence of gdm (defined using the international association of the diabetes and Pregnancy study groups criteria: Glucose cut-off values of ≥5.1\xa0mmol/l for fasting Plasma Glucose, and/or ≥10.0\xa0mmol/l for 1-h and/or ≥8.5\xa0mmol/l for 2-h post load), change in fasting Glucose and ogtt Glucose area under the curve from Preconception baseline to 28\xa0weeks’ Gestation, maternal wellbeing/mood, absence of excessive nausea and vomiting, adequate Pregnancy weight gain (institute of medicine criteria) and Vaginal Delivery rates\nreduction in maternal Micronutrient insufficiency, specifically less riboflavin, Vitamin B6, Vitamin B12, zinc and Vitamin D insufficiency, before and during Pregnancy\nalteration in Gut microbiota CONSISTENT with enhanced wellbeing\nalteration in maternal metabolomic and epigenetic biomarkers CONSISTENT with improved maternal and/or offspring wellbeing\nenhancement of Breast Milk Micronutrient content, altered Immunological factors, epigenetic and metabolomic profiles (subsample) and maintenance of healthy Lactogenesis\nsecondary offspring outcomes of the initial phase of the nipper study are:\nneonatal adiposity measured by pea pod\nBirthweight 2500–4000\xa0g, size for Gestational age at Birth and customised birthweight centile\nreduced adiposity gain during Infancy, analysed taking account of infant Feeding\nreduction in Cord Blood c-peptide as a marker of overall glycaemia during Gestation\npromotion of offspring wellbeing and healthy Cardiometabolic RISK FACTORS, including Visceral adiposity and markers of Insulin resistance, during infancy\nalteration in offspring metabolomic and epigenetic biomarkers in Perinatal samples, CONSISTENT with improved infant Metabolic and allergic Wellbeing\nalteration in Gut microbiota to a microbiota ASSOCIATED with infant Metabolic and allergic Wellbeing\n\ndata and biosample collection\nstudy data will be collected by trained research staff using an access-controlled, web-based database (medscinet, stockholm) managed with support from the data management staff of the mrc Lifecourse epidemiology unit and the singapore institute for clinical sciences.']	[('INCOMPLETE_EVIDENCE', 898), ('INCOMPLETE_EVIDENCE', 994), ('SUPERFICIAL_RELATIONSHIP', 1658), ('INCOMPLETE_EVIDENCE', 1835), ('SUPERFICIAL_RELATIONSHIP', 1945)]	5	[('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('GO_0007565', 'female pregnancy', 139, 'gestation'), ('GO_0007565', 'female pregnancy', 169, 'gestation'), ('GO_0007565', 'female pregnancy', 261, 'Pregnancy'), ('CHEBI_17234', 'glucose', 294, 'glucose'), ('UBERON_0001969', 'blood plasma', 344, 'plasma'), ('CHEBI_17234', 'glucose', 351, 'glucose'), ('CHEBI_17234', 'glucose', 445, 'glucose'), ('CHEBI_17234', 'glucose', 462, 'glucose'), ('GO_0007565', 'female pregnancy', 496, 'preconception'), ('GO_0007565', 'female pregnancy', 532, 'gestation'), ('GO_0007565', 'female pregnancy', 619, 'pregnancy'), ('UBERON_0001987', 'placenta', 678, 'vaginal'), ('GO_0007567', 'parturition', 686, 'delivery'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 723, 'micronutrient'), ('CHEBI_33237', 'vitamin D4', 782, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 794, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 816, 'vitamin D'), ('GO_0007565', 'female pregnancy', 859, 'pregnancy'), ('UBERON_0001555', 'digestive tract', 883, 'gut'), ('UBERON_0001348', 'brown adipose tissue', 1070, 'breast milk'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1082, 'micronutrient'), ('UBERON_0003222', 'flexor digitorum superficialis', 1113, 'immunological'), ('GO_0001554', 'luteolysis', 1211, 'lactogenesis'), ('GO_0007608', 'sensory perception of smell', 1338, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1372, 'gestational'), ('GO_0007567', 'parturition', 1391, 'birth'), ('UBERON_0000023', 'wing', 1462, 'infancy'), ('GO_0007631', 'feeding behavior', 1505, 'feeding'), ('UBERON_0002240', 'spinal cord', 1526, 'cord'), ('UBERON_0000178', 'blood', 1531, 'blood'), ('GO_0007565', 'female pregnancy', 1587, 'gestation'), ('GO_0007599', 'hemostasis', 1642, 'cardiometabolic'), ('UBERON_0002075', 'viscus', 1682, 'visceral'), ('PR_000045358', 'insulin family protein', 1716, 'insulin'), ('GO_0036268', 'swimming', 1816, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1816, 'perinatal'), ('GO_0051238', 'sequestering of metal ion', 1867, 'metabolic ... wellbeing'), ('UBERON_0001555', 'digestive tract', 1914, 'gut'), ('GO_0051238', 'sequestering of metal ion', 1968, 'metabolic ... wellbeing'), ('UBERON_0001281', 'hepatic sinusoid', 2220, 'Lifecourse')]
S126-PMC5418719	PMC5418719	5/2017	S126-PMC5418719	['these results SUGGEST Vitamin D deficiency is RELATED to impaired Glucose tolerance and Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 46)]	2	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 88, 'insulin')]
S0-PMC5539754	PMC5539754	8/2017	S0-PMC5539754	['season and Vitamin D status are INDEPENDENTLY ASSOCIATED with Glucose Homeostasis in Pregnancy\n\nabstract\n\nbackground\nVitamin D status and season are intrinsically LINKED, and both have been PROPOSED to be ASSOCIATED with Glucose Homeostasis in Pregnancy, with CONFLICTING results.']	[('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 163), ('INCOMPLETE_EVIDENCE', 190), ('SUPERFICIAL_RELATIONSHIP', 205), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 260)]	6	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0042593', 'glucose homeostasis', 62, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 117, 'Vitamin D'), ('CHEBI_17234', 'glucose', 221, 'glucose'), ('GO_0042593', 'glucose homeostasis', 221, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy')]
S16-PMC5539754	PMC5539754	8/2017	S16-PMC5539754	['the presence of Vitamin D receptors and Expression of 1-α-hydroxylase enzyme in Pancreatic Beta Cells SUGGEST that Vitamin D MAY BE a modulator of Insulin secretion and THUS, INFLUENCE Glucose Homeostasis [6].']	[('INCOMPLETE_EVIDENCE', 102), ('INCOMPLETE_EVIDENCE', 125), ('PROBABLE_UNDERSTANDING', 169), ('SUPERFICIAL_RELATIONSHIP', 175)]	4	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0010467', 'gene expression', 40, 'expression'), ('CL_0000169', 'type B pancreatic cell', 80, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 80, 'pancreatic'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('PR_000045358', 'insulin family protein', 147, 'insulin'), ('CHEBI_17234', 'glucose', 185, 'glucose'), ('GO_0042593', 'glucose homeostasis', 185, 'glucose homeostasis')]
S17-PMC5539754	PMC5539754	8/2017	S17-PMC5539754	['in Pregnancy, the ASSOCIATION between low Vitamin D levels and abnormalities in Glucose tolerance is the subject of scientific DEBATE, with SOME STUDIES reporting that maternal Insulin sensitivity, fasting Glucose and Gestational diabetes are not associated with 25ohd [7], WHILE others have FOUND inverse ASSOCIATIONS between 25ohd, fasting Glucose [8] and risk of Gestational diabetes [9].']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('INCOMPLETE_EVIDENCE', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 274), ('INCOMPLETE_EVIDENCE', 292), ('SUPERFICIAL_RELATIONSHIP', 306)]	6	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('PR_000045358', 'insulin family protein', 177, 'insulin'), ('CHEBI_17234', 'glucose', 206, 'glucose'), ('GO_0007565', 'female pregnancy', 218, 'gestational'), ('CHEBI_17234', 'glucose', 342, 'glucose'), ('GO_0007565', 'female pregnancy', 366, 'gestational')]
S30-PMC5539754	PMC5539754	8/2017	S30-PMC5539754	['due to the seasonal nature of 25Ohd concentrations in many parts of the world [32], and the OBSERVED ASSOCIATIONS between Vitamin D and Insulin resistance, it WOULD seem PRUDENT to HYPOTHESISE that seasonal variation of Glucose Homeostasis MAY BE MEDIATED through 25Ohd.']	[('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 101), ('FUTURE_PREDICTION', 159), ('IMPORTANT_CONSIDERATION', 170), ('FUTURE_WORK', 181), ('INCOMPLETE_EVIDENCE', 240), ('SUPERFICIAL_RELATIONSHIP', 247)]	7	"[('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 30, '25OHD'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('PR_000045358', 'insulin family protein', 136, 'insulin'), ('CHEBI_17234', 'glucose', 220, 'glucose'), ('GO_0042593', 'glucose homeostasis', 220, 'glucose homeostasis'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 264, '25OHD')]"
S104-PMC5539754	PMC5539754	8/2017	S104-PMC5539754	['additionally, those at risk of Vitamin D deficiency in early Pregnancy are more LIKELY to have increased fasting Glucose in late Pregnancy, INDEPENDENT of season.']	[('PROBABLE_UNDERSTANDING', 80), ('SUPERFICIAL_RELATIONSHIP', 140)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
S152-PMC5539754	PMC5539754	8/2017	S152-PMC5539754	['HOWEVER, UNLIKE the Hapo trial, we FOUND increased fasting Plasma Glucose in late Pregnancy among those at risk of Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 35)]	3	[('CHEBI_17883', 'hydrogen chloride', 20, 'HAPO'), ('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
S159-PMC5539754	PMC5539754	8/2017	S159-PMC5539754	['OUR FINDINGS SUGGEST that women at risk of Vitamin D deficiency in early Pregnancy have altered Glucose Metabolism in later Gestation, BUT the evidence is NOT CONSISTENT for Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('GO_0006006', 'glucose metabolic process', 96, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'gestation'), ('PR_000045358', 'insulin family protein', 174, 'insulin')]
S160-PMC5539754	PMC5539754	8/2017	S160-PMC5539754	['thus, RECOMMENDATIONS for Vitamin D supplementation to improve Glucose Homeostasis in Pregnancy CANNOT BE made BASED ON our results.']	[('FUTURE_WORK', 6), ('INCOMPLETE_EVIDENCE', 96), ('PROBABLE_UNDERSTANDING', 111)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0042593', 'glucose homeostasis', 63, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]
S175-PMC5539754	PMC5539754	8/2017	S175-PMC5539754	['participants at risk of Vitamin D deficiency at their first Antenatal visit were LIKELY to have increased fasting Glucose at 28\xa0weeks’ Gestation, REGARDLESS OF season.']	[('PROBABLE_UNDERSTANDING', 81), ('INCOMPLETE_EVIDENCE', 146)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007567', 'parturition', 60, 'antenatal'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0007565', 'female pregnancy', 135, 'gestation')]
S176-PMC5539754	PMC5539754	8/2017	S176-PMC5539754	['WHILE no interaction effect was OBSERVED between season and Vitamin D with regards to Glucose Homeostasis, it is well RECOGNISED that 25Ohd declines in winter, and is a modifiable FACTOR.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 32), ('PROBABLE_UNDERSTANDING', 118), ('SUPERFICIAL_RELATIONSHIP', 180)]	4	"[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('GO_0042593', 'glucose homeostasis', 86, 'glucose homeostasis'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 134, '25OHD')]"
S76-PMC5682869	PMC5682869	11/2017	S76-PMC5682869	['EARLY STUDIES concerning Vitamin D in Pregnancy SHOWED an ASSOCIATION with Preeclampsia and caesarean section but also Glucose tolerance, abnormal foetal Grown pattern, Preterm Birth and Reproductive failure.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 58)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 75, 'preeclampsia'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('GO_0040007', 'growth', 154, 'grown'), ('GO_0007565', 'female pregnancy', 169, 'preterm'), ('GO_0007567', 'parturition', 177, 'birth'), ('GO_0000003', 'reproduction', 187, 'reproductive')]
S493-PMC5941617	PMC5941617	5/2018	S493-PMC5941617	['SHOWED no difference in Vitamin D status between obese with or without impaired Glucose Homeostasis [450].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('GO_0042593', 'glucose homeostasis', 80, 'glucose homeostasis')]
S499-PMC5941617	PMC5941617	5/2018	S499-PMC5941617	['more RECENT FINDINGS have reported no influence of DIFFERENT Vitamin D supplementation schedules on Serum Lipid levels, Glucose Homeostasis, glycated hemoglobin and Pancreatic Insulin secretion [457–459].']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 51)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 100, 'serum'), ('CHEBI_18059', 'lipid', 106, 'lipid'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('GO_0042593', 'glucose homeostasis', 120, 'glucose homeostasis'), ('UBERON_0001264', 'pancreas', 165, 'pancreatic'), ('PR_000045358', 'insulin family protein', 176, 'insulin')]
S501-PMC5941617	PMC5941617	5/2018	S501-PMC5941617	['finally, two RECENT meta-analyses SHOWED that Vitamin D supplementation had no significant effect on Glucose and Insulin Metabolism [461] and on changes in the concentrations of inflammatory BIOMARKERS (C-Reactive Protein, tumor necrosis factor alpha, Il-6) in obese and overweight adolescents and Adults [462].']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 191)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0007369', 'gastrulation', 101, 'glucose ...'), ('GO_1901142', 'insulin metabolic process', 113, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 113, 'insulin'), ('PR_000005890', 'crooked neck-like protein 1', 203, 'C-reactive protein'), ('PR_000001470', 'interleukin-28B', 252, 'IL-6'), ('UBERON_0007023', 'adult organism', 298, 'adults')]
S7-PMC6039335	PMC6039335	7/2018	S7-PMC6039335	['nutritional factors, including Fat Metabolism, Digestion and Absorption Of Feed, Glucose/Starch availability, and Vitamin A, d, and c levels are IMPORTANT for imf deposition.']	[('IMPORTANT_CONSIDERATION', 145)]	1	[('GO_0006631', 'fatty acid metabolic process', 31, 'fat metabolism'), ('GO_0007586', 'digestion', 47, 'digestion ...'), ('GO_0030254', 'protein secretion by the type III secretion system', 61, 'absorption of feed'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('CHEBI_28017', 'starch', 89, 'starch'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin A')]
S23-PMC6039335	PMC6039335	7/2018	S23-PMC6039335	['factors AFFECTING imf deposition can be sub-categorized into Genetic (breed and sex differences, heritability), management (weaning age, castration, slaughter weight and age, and environment), and nutritional factors (Fat Metabolism, Fat Digestion and absorption, Glucose/Starch availability, roughage vs concentrate ratio, dietary energy and protein levels, Vitamins A, d, and c levels, fetal and neonatal nutritional programming, and stage-specific Feeding systems).']	[('SUPERFICIAL_RELATIONSHIP', 8)]	1	[('SO_0000704', 'gene', 61, 'genetic'), ('GO_0006631', 'fatty acid metabolic process', 218, 'fat metabolism'), ('GO_0009566', 'fertilization', 234, 'fat digestion'), ('CHEBI_17234', 'glucose', 264, 'glucose'), ('CHEBI_28017', 'starch', 272, 'starch'), ('CHEBI_27300', 'vitamin D', 359, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 368, 'A'), ('GO_0007631', 'feeding behavior', 451, 'feeding')]
S156-PMC6039335	PMC6039335	7/2018	S156-PMC6039335	['nutritional factors\nseveral nutritional factors including Fat Metabolism, fat Digestion and absorption, Glucose/Starch availability, roughage vs. concentrate ratio, dietary energy and protein levels, Vitamins A, d, and c levels, fetal nutritional programming, and stage-specific Feeding systems CAN AFFECT imf deposition.']	[('INCOMPLETE_EVIDENCE', 295), ('SUPERFICIAL_RELATIONSHIP', 299)]	2	[('GO_0006631', 'fatty acid metabolic process', 58, 'fat metabolism'), ('GO_0007586', 'digestion', 78, 'digestion'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('CHEBI_28017', 'starch', 112, 'starch'), ('CHEBI_27300', 'vitamin D', 200, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 209, 'A'), ('GO_0007631', 'feeding behavior', 279, 'feeding')]
